Table 1 |
|||
|
Frequency of selected autoantibodies in the CSRG cohort |
|||
|
n |
% |
Numbers not tested |
|
|
|
|||
|
CENP-B |
285 |
36% |
162 |
|
Centromere by IIF |
334 |
35% |
2 |
|
CENP-A |
275 |
34% |
162 |
|
Ro52/TRIM21 |
194 |
20% |
0 |
|
RNA polymerase III |
144 |
19% |
188 |
|
Topoisomerase I |
150 |
16% |
0 |
|
PM/Scl |
53 |
7% |
188 |
|
Ro60 |
53 |
6% |
0 |
|
U1 RNP |
59 |
6% |
0 |
|
Chromatin |
44 |
5% |
0 |
|
Sm |
39 |
4% |
0 |
|
SS-B/La |
26 |
3% |
0 |
|
Jo-I |
6 |
1% |
0 |
|
Ribosomal P |
14 |
1% |
0 |
|
|
|||
|
N = 963. CENP, centromere protein; IIF, indirect immunofluorescence; PM/Scl, polymyositis/scleroderma (exosome) autoantigen; RNP, ribonucleoprotein; Sm, Smith autoantigen; SS-B, Sjögren syndrome antigen B or La. |
|||
|
Hudson et al. Arthritis Research & Therapy 2012 14:R50 doi:10.1186/ar3763 |
|||
